Sunshine Biopharma - נכסים נקיים למניה בודדת SBFM

Sunshine Biopharma (SBFM) currently generates a stable cash flow through the sale of core generics, while growth potential is embedded in future macromolecule tests. The fair book value of the share clearly demonstrates the company's actual asset backing, with 230.60 showing the current value of the metric. Business prospects rely on the commercialization of oncology therapies and the launch of antiviral agents, while intellectual property guarantees monopoly pricing power.

This metric reflects the difference between the issuer's total assets and liabilities divided by the number of shares, allowing for an assessment of the intrinsic value of capital net of debt. By analyzing the reported book value per share, an investor determines the financial stability of Sunshine Biopharma (SBFM), where accumulated capital serves as the foundation for the long development cycle of proprietary anti-tumor drugs until their commercialization.